ClinicalTrials.gg
CompletedNCT00564954Updated Apr 27, 2012Results posted

A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)

A Phase 4 interventional study of Dex-methylphenidate hydrochloride extended-release (Focalin XR) and Placebo in Attention Deficit Hyperactivity Disorder, sponsored by Novartis Pharmaceuticals. Completed at 5 sites in United States. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2012-04-27.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis — none open to participants now, none under way, none of them phase 3. Attention Deficit Disorder with Hyperactivity · Novartis.

Enrollment
10th of 10
86 · median 146
Started
2007
with 1 other
Phase 4
2 of 10
none open now
Registered
7th of 10
by date

Among the 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis, this one is the 10th largest by enrollment, is one of 2 that started in 2007, is one of 2 in phase 4, and was the 7th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

None of the 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis is open now. The open studies under Attention Deficit Disorder with Hyperactivity, anywhere →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 6 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis as a file.
02

Study summary

This study compared the efficacy of dex-methylphenidate extended release 20 mg versus placebo during an 8-hour laboratory classroom day.

03

Conditions studied

  • Attention Deficit Hyperactivity Disorder

Keywords

  • ADHD
  • children
  • laboratory classroom
  • Attention Deficit Hyperactivity Disorder
04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects aged 6-12 years, inclusive.
  • Subjects meeting the criteria for ADHD of any type, as established by the K-SADS-PL (Kiddie Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version). If a DSM-IV-defined ADHD diagnosis is difficult to establish due to possible co-morbidity, the subject will not be enrolled into the study.
  • Subjects should be on a stabilized total daily dose or nearest equivalent of 40-60 mg methylphenidate or 20-30 mg of d-methylphenidate for at least two weeks prior to screening visit (Concerta® 36 mg and 54 mg is allowable)

Exclusion criteria

Exclusion Criteria:

  • Parent or guardian unable or unwilling to complete the Conner's ADHD/ Scale for Parents (CADS-P) and the Daily Diary Card
  • Diagnosed with a tic disorder or Tourette's syndrome
  • History of seizure disorder
  • The presence of a known medical condition that would preclude the use of methylphenidate. A history (within the past year) or presence of cardiovascular, cerebrovascular, renal, hepatic, gastrointestinal, pulmonary, immunological, hematological, endocrine, or neurological disease
  • , AST, GGPT or serum creatinine greater then 2X the at Screening
  • A history of psychiatric illness or substance use disorder (e.g., schizophrenia, bipolar disorder, autism, abuse or dependence, depression, severe Conduct Disorder or severe Oppositional defiant disorder)
  • Subjects who have participated in an trial within the past 4 weeks (28 days) are excluded
  • Subjects who are currently taking antidepressants or other psychotropic medication
  • Subjects who have initiated psychotherapy during the three months prior to randomization
  • Subjects with a positive urine drug screen
  • Subjects who have a history of poor response or intolerance to methylphenidate or d-methylphenidate

Other protocol defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Dex-methylphenidate hydrochloride (Focalin XR)

    20 mg capsule orally once a day for 7 days

    Drug: Dex-methylphenidate hydrochloride extended-release (Focalin XR)

  • Placebo comparator
    Placebo

    orally once a day for 7 days

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Pre-dose (0 hr [Hour]) on the Swanson, Kotkin, Agler, M-Flynn & Pelham (SKAMP) Rating Scale Combined Score at 0.5 Hour During the 8- Hour Laboratory Classroom Day

    SKAMP rating scale is comprised of 13 questions (7 questions on attention and 6 questions on deportment) evaluating classroom behavior; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 78.

    Time frame: 0 hr and 0.5 hr post-dose

Secondary outcomes

  1. Change From Pre-dose (0 hr) in SKAMP Combined Score at All Times Excluding the 0.5 Hour Timepoint (Hours 1, 2, 4, 6, 8)

    SKAMP rating scale is comprised of 13 questions (7 questions on attention and 6 questions on deportment) evaluating classroom behavior; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 78.

    Time frame: 0, 1, 2, 4, 6, and 8 hr

  2. Change From Pre-dose in SKAMP Attention Score at All Timepoints (0.5, 1, 2, 4, 6, 8)

    SKAMP attention sub-scale is comprised of 7 questions evaluating concentration in the classroom; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 42.

    Time frame: 0, 0.5, 1, 2, 4, 6, and 8 hours

  3. Change From Pre-dose in SKAMP Deportment Score

    SKAMP deportment sub-scale is comprised of 6 questions on behavior in the classroom; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 36.

    Time frame: 0, 0.5, 1, 2, 4, 6 and 8 hours

  4. Change From Pre-dose (0 hr.) in Permanent Product Measure of Performance (PERMP) Math Test-Attempted Scores at All Timepoints (0.5, 1, 2, 4, 6, 8)

    Number of math questions attempted within a 10 minute period.

    Time frame: 0, 0.5, 1, 2, 4, 6 and 8 hours

  5. Change From Pre-dose in Number of Math Questions Answered Correctly on the Permanent Product Measure of Performance (PERMP) Math Test

    Number of math questions answered correctly within a 10 minute period.

    Time frame: 0, 0.5, 1, 2, 4, 6 and 8 hours

07

Results

Posted Mar 30, 2009

Participant flow

Period 1- 1 Week
Participant flow — Period 1- 1 Week
MilestoneDex-methylphenidate Hydrochloride (Focalin XR) Then PlaceboPlacebo Then Dex-methylphenidate Hydrochloride (Focalin XR)
Started4442
Completed4442
Not completed00
Period 2- 1 Week
Participant flow — Period 2- 1 Week
MilestoneDex-methylphenidate Hydrochloride (Focalin XR) Then PlaceboPlacebo Then Dex-methylphenidate Hydrochloride (Focalin XR)
Started4442
Completed4442
Not completed00

Outcome measures

SecondaryChange From Pre-dose (0 hr) in SKAMP Combined Score at All Times Excluding the 0.5 Hour Timepoint (Hours 1, 2, 4, 6, 8)

SKAMP rating scale is comprised of 13 questions (7 questions on attention and 6 questions on deportment) evaluating classroom behavior; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 78.

Time frame:
0, 1, 2, 4, 6, and 8 hr
Reported as:
Least squares mean · score on a scale
Change From Pre-dose (0 hr) in SKAMP Combined Score at All Times Excluding the 0.5 Hour Timepoint (Hours 1, 2, 4, 6, 8)
score on a scaleDex-methylphenidate Hydrochloride (Focalin XR)Placebo
1 hour-6.358 ± 0.9935.670 ± 0.991
2 hours-11.573 ± 0.8565.467 ± 0.854
4 hours-11.395 ± 0.8473.925 ± 0.844
6 hours-10.622 ± 0.9505.346 ± 0.952
8 hours-10.260 ± 0.9883.621 ± 0.986
SecondaryChange From Pre-dose in SKAMP Attention Score at All Timepoints (0.5, 1, 2, 4, 6, 8)

SKAMP attention sub-scale is comprised of 7 questions evaluating concentration in the classroom; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 42.

Time frame:
0, 0.5, 1, 2, 4, 6, and 8 hours
Reported as:
Least squares mean · score on a scale
Change From Pre-dose in SKAMP Attention Score at All Timepoints (0.5, 1, 2, 4, 6, 8)
score on a scaleDex-methylphenidate Hydrochloride (Focalin XR)Placebo
0.5 hour-0.825 ± 0.5240.862 ± 0.520
1 hour-4.208 ± 0.5892.304 ± 0.584
2 hours-6.591 ± 0.5072.465 ± 0.504
4 hours-6.722 ± 0.5061.183 ± 0.503
6 hours-5.819 ± 0.5822.715 ± 0.580
8 hours-6.061 ± 0.5841.415 ± 0.580
SecondaryChange From Pre-dose in SKAMP Deportment Score

SKAMP deportment sub-scale is comprised of 6 questions on behavior in the classroom; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 36.

Time frame:
0, 0.5, 1, 2, 4, 6 and 8 hours
Reported as:
Least squares mean · score on a scale
Change From Pre-dose in SKAMP Deportment Score
score on a scaleDex-methylphenidate Hydrochloride (Focalin XR)Placebo
0.5 hour0.127 ± 0.5502.226 ± 0.550
1 hour-1.863 ± 0.5643.103 ± 0.564
2 hours-4.850 ± 0.4992.881 ± 0.499
4 hours-4.420 ± 0.5262.511 ± 0.526
6 hours-4.614 ± 0.5412.393 ± 0.541
8 hours-3.939 ± 0.5601.969 ± 0.560
SecondaryChange From Pre-dose (0 hr.) in Permanent Product Measure of Performance (PERMP) Math Test-Attempted Scores at All Timepoints (0.5, 1, 2, 4, 6, 8)

Number of math questions attempted within a 10 minute period.

Time frame:
0, 0.5, 1, 2, 4, 6 and 8 hours
Reported as:
Least squares mean · questions attempted
Change From Pre-dose (0 hr.) in Permanent Product Measure of Performance (PERMP) Math Test-Attempted Scores at All Timepoints (0.5, 1, 2, 4, 6, 8)
questions attemptedDex-methylphenidate Hydrochloride (Focalin XR)Placebo
0.5 hour6.93 ± 2.96-4.74 ± 2.96
1 hour33.26 ± 3.66-12.18 ± 3.66
2 hours45.52 ± 3.61-10.19 ± 3.61
4 hours45.01 ± 3.60-7.42 ± 3.60
6 hours37.33 ± 3.82-16.70 ± 3.84
8 hours44.04 ± 3.50-10.08 ± 3.50
SecondaryChange From Pre-dose in Number of Math Questions Answered Correctly on the Permanent Product Measure of Performance (PERMP) Math Test

Number of math questions answered correctly within a 10 minute period.

Time frame:
0, 0.5, 1, 2, 4, 6 and 8 hours
Reported as:
Least squares mean · questions correct
Change From Pre-dose in Number of Math Questions Answered Correctly on the Permanent Product Measure of Performance (PERMP) Math Test
questions correctDex-methylphenidate Hydrochloride (Focalin XR)Placebo
0.5 hour7.10 ± 2.72-5.96 ± 2.72
1 hour31.10 ± 3.34-13.21 ± 3.34
2 hours44.92 ± 3.44-11.09 ± 3.44
4 hours43.64 ± 3.37-7.52 ± 3.37
6 hours37.78 ± 3.55-16.90 ± 3.57
8 hours43.37 ± 3.40-11.44 ± 3.40
PrimaryChange From Pre-dose (0 hr [Hour]) on the Swanson, Kotkin, Agler, M-Flynn & Pelham (SKAMP) Rating Scale Combined Score at 0.5 Hour During the 8- Hour Laboratory Classroom Day

SKAMP rating scale is comprised of 13 questions (7 questions on attention and 6 questions on deportment) evaluating classroom behavior; answers to each question range from 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 78.

Time frame:
0 hr and 0.5 hr post-dose
Reported as:
Least squares mean · score on a scale
Change From Pre-dose (0 hr [Hour]) on the Swanson, Kotkin, Agler, M-Flynn & Pelham (SKAMP) Rating Scale Combined Score at 0.5 Hour During the 8- Hour Laboratory Classroom Day
score on a scaleDex-methylphenidate Hydrochloride (Focalin XR)Placebo
Change From Pre-dose (0 hr [Hour]) on the Swanson, Kotkin, Agler, M-Flynn & Pelham (SKAMP) Rating Scale Combined Score at 0.5 Hour During the 8- Hour Laboratory Classroom Day-0.969 ± 0.9093.336 ± 0.907

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dex-methylphenidate Hydrochloride (Focalin XR)—0/86 (0%)0/86 (0%)
Placebo—0/86 (0%)0/86 (0%)

Baseline characteristics

Age Continuous
Age Continuous(years)Dex-methylphenidate Hydrochloride (Focalin XR) Then PlaceboPlacebo Then Dex-methylphenidate Hydrochloride (Focalin XR)Total
Mean9.5 ± 2.09.4 ± 1.49.5 ± 1.7
Sex: Female, Male
Sex: Female, Male(Participants)Dex-methylphenidate Hydrochloride (Focalin XR) Then PlaceboPlacebo Then Dex-methylphenidate Hydrochloride (Focalin XR)Total
Female161733
Male282553
08

Study locations

5 sites
  • Novartis Investigative Site
    Little Rock, Arkansas 72205, United States
  • Novartis Investigative Site
    Winter Park, Florida 32792, United States
  • Novartis Investigative Site
    Las Vegas, Nevada 89128, United States
  • Novartis Investigative Site
    Houston, Texas 77007, United States
  • Novartis Investigative Site
    Lubbock, Texas 79423, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Nov 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2009, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2007
First posted
Nov 29, 2007
Start
Oct 2007
Primary completionActual
Nov 2007
CompletionActual
Nov 2007
Results first posted
Mar 30, 2009
Last update
Apr 27, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00564954
Responsible party
Sponsor
First posted
Nov 29, 2007
Start date
Oct 2007
Primary completion
Nov 2007
Completion
Nov 2007
Results posted
Mar 30, 2009
Last update
Apr 27, 2012

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmethylphenidate

Start the discussion